A first-in-human clinical trial of RGX-181
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs RGX-181 (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions; First in man
- Sponsors REGENXBIO
- 05 Nov 2019 According to a REGENXBIO media release, the company intends to sub,it an IND for this study in the second half of 2020, following additional preclinical development and analyses to support clinical development.
- 31 Jan 2019 According to a REGENXBIO media release, the company is looking forward to filing an IND with the FDA for this clinical trial in the second half of 2019 to enable initiation of a first-in-human clinical trial.
- 12 Sep 2018 New trial record